Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight presentations, including one oral presentation, at The Liver Meeting^® 2025, being held November 7 – 11, 2025 in Washington, D.C. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Read more at globenewswire.com